Full-Time

Actuary 3

Deadline 9/15/26
Aflac

Aflac

10,001+ employees

Supplemental health and life insurance provider

Compensation Overview

$100k - $130k/yr

+ Annual bonuses + Company stock purchase opportunity

Columbus, GA, USA + 1 more

More locations: Columbia, SC, USA

Hybrid

At least 60% of the work week is in an Aflac office; the remaining time may be worked from home within the continental US.

Bachelor's

Category
Insurance (1)
Required Skills
SQL
Mainframe Computing
Data Analysis
Excel/Numbers/Sheets
Financial Modeling

Get referred to Aflac

See people who can refer or advise you

Requirements
  • Proficiency coding models in Excel, mainframe applications, SQL, MG-Alfa, or similar actuarial software.
  • A bachelor's degree in actuarial science, mathematics, computer science, or a related field.
  • An Associate of the Society of Actuaries designation from the Society of Actuaries is required, along with a commitment to continue toward Fellow of the Society of Actuaries designation.
  • Current candidacy in or qualification to become a candidate in the Aflac Actuarial Development Program.
  • Three years of professional job-related work experience, or an equivalent combination of education and experience.
  • Knowledge of actuarial standards of practice.
  • Ability to analyze statistical data, including morbidity, mortality, and termination experience, as well as policy provisions, state regulations, and related documents.
Responsibilities
  • Perform data analysis, synthesize findings, and develop materials and presentations of results.
  • Identify, set, and defend actuarial and financial assumptions.
  • Develop, enhance, and deliver actuarial and financial models that evaluate risk.
  • Lead projects, including projects with cross-functional accountabilities, and reprioritize work or seek resources as needed.
  • Align actuarial analysis and findings with broader organizational goals and connect technical analysis to business outcomes.
  • Develop projects, plans, and priorities consistent with business initiatives and goals.
  • Develop actions leading to business goals based on actuarial or financial findings.
  • Provide timely analysis and recommendations, including when data is incomplete.
  • Interpret business and technical information to influence key decision-makers and stakeholders.
  • Build agreement, commitment, cooperation, and support for recommendations.
  • Develop staff or others through business-leadership competencies and provide cross-functional project or mentoring opportunities.
  • Ensure others understand their roles in achieving area and business priorities and involve employees in decision-making, milestone setting, one-on-ones, and key business information.
  • Solve challenging actuarial questions using actuarial standards of practice and business acumen.
  • Work with product development, financial, compliance, and Japanese colleagues to complete assignments on schedule.
  • Review and analyze statistical data, policy provisions, state regulations, and other documents.
  • Apply judgment, business acumen, creativity, and latitude to plan and accomplish goals.
  • Communicate actuarial findings to managers and executives to support business decisions.
  • Represent the department in internal and external groups for the benefit of Aflac.
  • Perform other duties as required.
Desired Qualifications
  • Understanding of Aflac's products and business functions.
  • Ability to participate in new and challenging work experiences outside one's functional area.

Aflac provides supplemental health and life insurance products to individuals and families, operating mainly in two regions: Aflac Japan and Aflac U.S. Its policies are designed to cover out-of-pocket costs from health events and income loss, including cancer, critical illness, accidents, hospital stays, and life events. These benefits are paid directly to policyholders to help manage medical expenses not fully covered by primary insurance. The products are distributed through a network of independent agents, brokers, and financial advisors, enabling a high-volume, low-premium model that supports a large, stable customer base and ongoing revenue. Japan is its largest market, and the company uses this broad distribution and scale to differentiate itself from competitors. The goal is to provide straightforward financial protection against unexpected health-related costs while expanding its presence in the U.S. and Japanese markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

Columbus, Georgia

Founded

1955

Get referred to Aflac

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 U.S. sales rose 2.6%, led by group voluntary and dental coverage.
  • Aflac returned $1.3 billion in Q2 2026, reinforcing dividend and buyback credibility.
  • Japan pretax margin reached 34.3% in Q2 2026, supporting ROE expansion.

What critics are saying

  • Q2 2026 Japan sales fell 5.6%, exposing dependence on product launch timing.
  • Persistency slipped to 92.7% in Q2 2026, hurting earned premiums and growth.
  • If Japan lapses, FX pressure, and slower U.S. growth persist, valuation stalls.

What makes Aflac unique

  • Aflac Japan keeps leading cancer and medical policies in force in 2026.
  • Aflac’s 2026 product refresh, Miraito, Tsumitasu, and Anshin Palette, expands cross-selling.
  • Aflac’s 2026 capital flexibility includes a shelf registration and regular yen funding.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Paid Holidays

Hybrid Work Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Aug 15th, 2026
Aflac Q2 revenue falls 6.9% as Japan sales decline after Miraito cancer insurance launch

Aflac's second quarter results disappointed investors despite meeting Wall Street expectations, with revenue declining 6.9% year-on-year to $4.22 billion. The insurance giant attributed the sales drop largely to difficult comparisons following last year's launch of its Miraito cancer insurance product in Japan. Chief Executive Daniel Amos said new Japanese offerings like Tsumitasu and Anshin Palette generated solid growth. US sales grew modestly, supported by group voluntary products and network dental and vision offerings. During the earnings call, analysts pressed management on several key issues. Questions focused on the sustainability of asset repositioning efforts, appetite for larger acquisitions, sequential declines in Japanese medical sales, and the impact of inflation on policy lapse rates. Amos said Aflac remains open to strategic acquisitions but will maintain discipline, favouring smaller deals that fit operationally and financially.

Yahoo Finance
Aug 11th, 2026
Aflac Q2 sales fall 6.9% to $4.22B as Japan product refresh and U.S. group growth offset decline

Aflac reported second-quarter revenue of $4.22 billion, meeting Wall Street expectations but declining 6.9% year on year. Adjusted earnings per share of $1.75 also met analyst estimates. The supplemental insurance provider attributed the revenue decline to tough comparisons in Japan following last year's cancer insurance product launch and shifting consumer preferences. However, CEO Daniel Amos highlighted solid growth from new offerings including Tsumitasu and Anshin Palette. In the US, group voluntary products and network dental and vision sales showed strength, with dental and vision product sales rising 47%. The company maintained expense discipline despite inflationary pressures. Looking ahead, Aflac plans to focus on product innovation in Japan, continued US group product momentum, and enhanced capital management. Management emphasised its commitment to dividend growth and share repurchases.

Yahoo Finance
Aug 6th, 2026
Aflac misses Q2 revenue estimates as sales fall 9.2% to $4.12B

Aflac reported second-quarter revenue of $4.12 billion, missing analyst estimates of $4.23 billion and marking a 9.2% year-on-year decline. The supplemental insurance provider's adjusted earnings per share of $1.75 met expectations. The company's book value per share reached $60.35, beating estimates by 9.3% and showing 18.7% year-on-year growth. Pre-tax profit was $995 million, with a 24.2% margin. Chairman and CEO Daniel P. Amos highlighted solid earnings execution and new opportunities in Japan through products including Anshin Palette medical insurance and Miraito cancer insurance. In the US, Aflac is focusing on supplemental health products for employers. Over the past five years, Aflac's revenue has declined at a 5.1% annual rate, reflecting ongoing demand challenges.

PR Newswire
Aug 6th, 2026
Aflac reports Q2 net earnings of $825M, declares $0.61 quarterly dividend

Aflac Incorporated reported second quarter 2026 results with net earnings of $825 million, or $1.63 per diluted share, compared with $599 million, or $1.11 per diluted share a year ago. Total revenues decreased 1.0% to $4.1 billion. Adjusted earnings were $883 million, down 7.7% from $957 million in the prior year quarter. Adjusted earnings per diluted share decreased 1.7% to $1.75. The company returned $1.3 billion to shareholders through $983 million in share repurchases and $309 million in dividends. Chairman and CEO Daniel Amos highlighted successful product initiatives in Japan and focus on supplemental health products in the US. The board declared a third quarter dividend of $0.61 per share, payable on 1 September 2026 to shareholders of record on 19 August 2026.

Yahoo Finance
Jul 2nd, 2026
Aflac files omnibus shelf registration and launches Fit Checks cancer screening campaign with Rachel Zoe

Aflac has filed an omnibus shelf registration statement covering common stock, debt securities, warrants and other instruments, whilst launching its Fit Checks cancer screening awareness campaign with fashion designer Rachel Zoe. The campaign uses QR-enabled fashion pieces to link wearable design with cancer risk education. The moves demonstrate Aflac's strategy of combining capital markets flexibility with brand-building in preventive health. However, the initiatives don't materially change near-term earnings catalysts or key risks including declining Japanese premiums, currency volatility and investment income pressure. The company's second quarter 2026 earnings release, scheduled for 6-7 August, will provide insight into whether new products and digital initiatives are improving premium trends and margins in Japan and the US, Aflac's primary markets.